Rogaine efficacy study in non-Caucasian women suggested by advisory cmte..
This article was originally published in The Tan Sheet
Executive Summary
ROGAINE PHASE IV EFFICACY STUDY IN NON-CAUCASIAN WOMEN SUGGESTED by members of the Nonprescription Drugs, Dermatologic and Ophthalmic Drugs Advisory Committees at a Nov. 17 joint meeting. Dermatologic committee member Denise Buntin, MD, Vanderbilt University Medical Center, pointed out that Pharmacia & Upjohn did not submit much data on the use of Rogaine (2%) minoxidil hair regrowth treatment for androgenetic alopecia, or hereditary baldness, in non-Caucasian women.